Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome – role of romidepsin in the current therapeutic landscape and implications for future practice

摘要: Introduction: Cutaneous T-cell lymphoma (CTCL) encompasses a rare group of hematologic malignancies, in which complete and durable responses to treatment are often elusive, with patients requiring multiple successive lines therapy. Traditional chemotherapeutic agents do not seem deliver lasting without cumulative toxicity. In this context, focus has shifted biologic immunomodulatory agents, the histone deacetylase inhibitor (HDACi) romidepsin attracted interest for its tolerability proven efficacy around one-third two pivotal clinical trials.Areas covered: review, we survey existing preclinical data from discovery use prospective trials. Pharmacology, toxicity current market overview including potential comparators also examined.Expert opinion: There is clear demonstrable role CTCL given convincing long-term Phase II data. No...